natgillin/translations-raw huggingface dataset:
A compound comprising a modified oligonucleotide and a conjugate group, wherein the modified oligonucleotide consists of 20 linked nucleosides and has a nucleobase sequence comprising 20 contiguous nucleobases complementary to an equal length portion of nucleobases 3533 to 3552 of SEQ ID NO: 3, wherein the nucleobase sequence of the modified oligonucleotide is 100% complementary to SEQ ID NO: 3; and wherein the conjugate group comprises: 
Spoj koji sadrži modificirani oligonukleotid i konjugatnu grupu, pri čemu se modificirani oligonukleotid sastoji od 12 do 30 povezanih nukleozida i ima sekvencu nukleobaza najmanje 85% komplementarnu SEQ ID NO: 1 koja kodira virus hepatitisa B (HBV) i pri čemu konjugatna grupa sadrži:
The apparatus (10) of claim 1, characterized by comprising a marking device that applies an identification marker to each of the carrier tablets (1000), wherein said marking device is chosen from the group consisting of a second pad-printing device, a laser marker, an inkjet device or a rotogravure device. 
Uređaj (10) u skladu s patentnim zahtjevom 1, naznačen time što sadrži napravu za markiranje koja stavlja identifikacijski marker na svaku od nosivih tableta (1000), gdje se navedenu napravu za markiranje bira iz skupine koju čine druga naprava za tamponski otisak, laserski marker, tintna naprava ili naprava za rotogravuru.
It is preferred that the weight ratio of antisticking agent to the sustained release polymer, is at least 1:1 and up to 1:10, preferably from 1:2 to 1:5. 
Poželjno je da težinski odnos sredstva protiv sljepljivanja prema polimeru za produljeno otpuštanje u najmanju ruku 1:1, pa do 1:10, po mogućnosti od 1:2 do 1:5.
The enriching stage 6 also comprises a pressurised water feed line 61, which takes water from a water source 62 and conveys it to the nozzle 60, where the water is nebulised in the process air flow. 
- < liniju za uvođenje vode (61), koja uzima vodu iz izvora vode (62) i dobavlja je do sapnice (60), gdje se voda fino raspršuje u vidu magle u tok zraka za postupak;
The present invention includes a method of treating conditions such as asthma, dermatitis, inflammatory bowel disease, Alzheimer's disease, psychotic major depression, neuropathy, transplant rejection, multiple sclerosis, chronic uveitis, or chronic obstructive pulmonary disease in a subject comprising administering to the subject a compound or salt of the present invention. 
Spoj formule (I), ili njegova sol, naznačen time što se upotrebljava za liječenje astme, dermatitisa, upalne bolesti crijeva, Alzheimerove bolesti, psihotične jake depresije, neuropatije, odbacivanja presatka, multiple skleroze, kroničnog uveitisa, kronične opstruktivne bolesti pluća, ili reumatoidnog artritisa.
The roll of any of the preceding claims, wherein the Cr content in the steel composition is between 7.3 - loess than (<) 8.0 % Cr in terms of % per weight of total roll weight. 
Valjak prema prethodnim zahtjevima, pri čemu sadržaj Cr u sastavu čelika iznosi između 7,3-manje od (<) 8 % Cr u postotnoj težini ukupne težine valjka.
A power point as claimed in claim 7, characterised in that said card comprises holes through which said light source (26, 28) is visible from the outside. 
Točka napajanja u skladu s patentnim zahtjevom 6, naznačena time što navedena kartica ima rupe kroz koje se navedeni izvor svjetla (26, 28) vidi izvana.
The process according to one of the claims 25 to 27, wherein the water to be purified contains at least one compound selected from polycyclic compounds, cholesterol, and/or endocrine disrupting compounds. 
Postupak prema zahtjevu 17, pri čemu voda koju treba pročistiti sadrži nečistoće teških metala, organske nečistoće, mikroorganizme, i/ili barem jedan spoj izabran od policikličnih spojeva, kolesterola, i/ili spojeva koji izazivaju endokrine poremećaje.
The composition of claim 1, wherein the recombinant human lysosomal alpha-mannosidase is obtained from a cell culture. 
Postupak šaržne ili kontinuirane proizvodnje rekombinantne ljudske lizosomske a-manozidaze, naznačen time što se sastoji u sljedećim koracima:
The communication method according to one of claims 6-9, wherein the first component carrier is a primary cell and the second component carrier is a secondary cell. 
Komunikacijski postupak u skladu s jednim od zahtjeva 7 do 11, naznačen time što je prvi nosač komponenti primarna stanica, a drugi nosač komponenti je sekundarna stanica.
L is tosyl or mesyl; reacting the diastereomeric mixture of formula VIIa (S,R+R,R), or alternatively reacting separately the diastereomer VIIa (S,R) and the diastereomer VIIa (R,R) with a base to obtain the corresponding diastereomeric mixture of formula VIIIa (S,R+R,R) 
OH pri čemu je L tosil ili mesil; reakciju dijasteroizomerne mješavine formule Vlla (S, R+R, R), ili alternativno reakciju odvojenog dijasteromera VIla (S, R) i dijasteromera VIla (R, R) s bazom, za dobivanje odgovarajuće dijasteroizomerne mješavine formule VIIIa (S, R+R, R) i.
Ceramic tile as claimed in claim 4, wherein the opening is rectangular and wherein the upper surface comprises at least four zones, wherein each zone connects to a side of the rectangular opening. 
Keramička obložna pločica (12, 13, 14, 15) u skladu s patentnim zahtjevom 1, naznačena time što je otvor pravokutan, te što gornja površina ima najmanje četiri područja, gdje je svako područje povezano s jednom stranom pravokutnog otvora.
An isolated compound of formula I: where: is hydroxy or B-D-xylopyranoside, 
Formulacija izoliranog spoja formule I:, gdje: je hidroksi ili B-d-ksilopiranozid,
a diuretic agent, or (viii) a hormone or therapeutic peptide or protein, or 
diuretičkog sredstva, ili (viii) hormona ili terapijskog peptida ili proteina, ili
Furthermore, by applying excipients in the compositions of the pellets according to the invention, the quality of the pellets and the quantity of the amount of pellets falling into the preferable particle size region can be improved. 
Nadalje, primjenom ekscipijenata u smjesama granula sukladno ovom izumu, kakvoća granula i broj granula koje su unutar poželjnog raspona veličine mogu se poboljšati.
Provided herein are compounds according to Formula (I): wherein: 
PATENTNI ZAHTJEVI Spoj prema Formuli (Ia): pri čemu:
Deeper engraving will furthermore result in a higher local magnetic field change, and is thus a preferred option. 
Osim toga, dublji urezi stvaraju snažniju lokalnu promjenu magnetskog polja i zato predstavljaju poželjno rješenje.
Since the data processing system 7 is inside the cabinet 2, it is much more difficult to tamper with compared with the previous apparatus and is therefore safer. 
Budući da se sustav za obradu podataka 7 nalazi unutar ormarića 2, mnogo je teže neovlašteno ulaziti u uređaj u usporedbi s prijašnjim uređajem i stoga je ovaj uređaj sigurniji.
The compound of any one of clauses 1-27, wherein R6 is selected from the group consisting of -OH, C1-C6 alkoxy, -OC(O)-C1-C6 alkyl, and -OC(O)phenyl. The compound of clause 28, wherein R6 is -OH. 
Spoj prema bilo kojem od zahtjeva 1-11, pri čemu Rs je odabran od skupine koja se sastoji od -OH, C;-Cg alkoksi, -OC(O)-C1-Cg alkila, 1 -OC(O)fenila, izborno pri čemu Re je -OH; i/ili pri čemu R; je Ci-C4 alkil, izborno pri čemu R; je -CHa.
The method of claim 7, wherein X42 is CR44, and R43 and R44 are, independently, selected from the group consisting of —H, methyl, ethyl, propyl, isopropyl, or cyclopropyl. 
Spoj prema zahtjevu 34, pri čemu Xy je CRa4 1 Rag 1 Rag su nezavisno izabrani iz skupine koju čine -H, metil, etil, propil, izopropil i ciklopropil.
The system of claim 2 wherein said heating device is a microwave heater. 
Sustav prema patentnom zahtjevu 2, naznačen time da je navedeni grijaći uređaj mikrovalni grijač.
The agent of claim 1 for the use of claim 1, wherein the spinal canal stenosis is cervical spinal canal stenosis, thoracic spinal canal stenosis, lumbar spinal canal stenosis, diffuse spinal canal stenosis or sacral stenosis. 
Sredstvo u skladu s patentnim zahtjevom 1, namijenjeno upotrebi u skladu s patentnim zahtjevom 1, naznačeno time što je stenoza kralježničnog kanala stenoza kanala cervikalne kralježnice, stenoza kanala torakalne kralježnice, stenoza kanala lumbalne kralježnice, difuzna stenoza kralježničnog kanala 1li stenoza kanala sakralne kralježnice.
For example, the gelation time can be controlled through the amplitude of the ultrasonication and the concentration of the silk fibroin solution. 
Postupak prema zahtjevu 7, gdje se vrijeme geliranja kontrolira preko amplitude ultrazvuka i koncentracije otopine fibroina svile.
One embodiment of the present invention pertains to compounds having Formula (Ih): wherein: Ring A is substituted with 1 or 2 substituents selected from the group consisting of halogen, n-propyl, n-butyl, C1-4 alkoxy and C3-5 cycloalkyl; or a pharmaceutically acceptable salt, solvate or hydrate thereof. 
Jedan oblik prikazanog izuma se odnosi na spojeve Formule (Ih): gdje Prsten A je po izboru supstituiran sa 1 ili 2 supstituenda izabrana iz skupine koju čine halogen, n-propil, n-butil, C,.4 alkoksi i C,.5 cikloalkil; ili na njihove farmaceutski prihvatljive soli, solvate ili hidrate.
The peptide according to claim 1 or 2 which is fused to the N-terminal amino acids of the HLA-DR antigen-associated invariant chain (Ii). 
Peptid u skladu s patentnim zahtjevom 1 ili 2, koji je fuzioniran u N-terminalne aminokiseline HLA-DR invarijantnog lanca vezanog za antigene (Ii).
The method according to claim 23, wherein the at least one mains electricity cable, the at least one low voltage electrical cable, the at least one water supply pipe, and the at least one water sewage pipe extend within a second shaft extending along a wall of the module. 
Postupak sukladno zahtjevu 9, wpri čemu se navedeni glavni električni kabel, navedeni električni kabel niskog napona, navedena cijsv za opskrbu vodom, i navedena cijev za odvod vode, pružaju duž drugog otvora za tehničke instalacije.
A process for the preparation of a-carboxamide pyrrolidine derivatives of formula (I), wherein 
Proces pripreme derivata a-karboksamid pirolidina formule (I):
introducing in a first step either: (i) a carbon dioxide generating compound, (ii) a carbon dioxide generating compound and an acid, or (iii) an acid in the water to be used for the preparation of the solution, and then introducing calcium carbonate, either in dry form or as a suspension in a second step in the water, or 
B) uvođenje u prvom koraku ili: (i) spoja koji stvara ugljikov dioksid, (ii) spoja koji stvara ugljikov dioksid i kiseline, ili (iii) kiseline u vodu koja će se koristiti za pripremanje otopine, te zatim uvođenje kalcijevog karbonata, bilo u suhom obliku ili kao suspenzije u drugom koraku u vodu, ili
The device according to claim 1, wherein outside the anchoring regions, the cross-section of the solid core is circular. 
Uređaj u skladu s patentnim zahtjevom 1 ili 2, naznačen time što je, izvan navedenih područja sidrenja (5), presjek navedene jezgre (1) kružnog oblika.
The image processing apparatus according to any of claims 1 to 6, wherein the processed image generating device (22) changes the weighting mode in accordance with information representing an amount of exposure of the original image (P0) upon radiography. 
Uređaj za obradu slike prema bilo kojem od zahtjeva 1 do 6, naznačen time, da uređaj za stvaranje obrađene slike (22) mijenja način opterećenja težinskim faktorom u skladu s informacijom koja predstavlja količinu ekspozicije originalne slike (PO) nakon radiografije.
The method according to claim 5, wherein the E1 A coding sequence and at least one of the E1B-19K and E1B-55K coding sequences are separated by at least 34.5 kb. 
Rekombinantna molekula ili skup od barem dvije molekule nuklemske kiseline prema zahtjevu 5, naznačena time da su navedena sekvenca nukleinske kiseline koja kodira El A protein i sekvenca nukleinske kiseline koja kodira barem jedan E1B protein odvojene sa barem 34.5 kb,
the cup body (22) is seated within the shell (14) so as to define there between a gap; wherein 
(22) pomoću navedene plastične obloge smješteni samo lokalno unutar navedene staze za kontakte (3).
two or more saddle coils coupled to the confinement chamber and, an ion pellet injector coupled to the confinement chamber. 
dvije ili više sedlastih zavojnica spojenih sa zapornom komorom i jedan injektor ionskih peleta, koji je spojen sa zapornom komorom.
LC-(ApcI)MS liquid chromatography-atmospheric pressure chemical ionization mass spectrometry 
LC-(ApcI)MS tekućinska kromatografija-atmosferski tlak kemijska ionizacija masena spektrometrija s.d.
The method of claim 1, wherein the compound is 6-bromo-8-(methyl-D3)-2-(trifluoromethyl)-2H-chromene-3-carboxylic acid, or a salt thereof. 
3. - Deuterirani benzopiranski spoj ili farmaceutski prihvatljiva sol prema patentnom zahtjevu 2, naznačeno time što je spoj 6-(metil-D3)-2-(trifluorometil)-2H-kromen-3-karboksilna kiselina ili njegova sol.
The peptide according to any of claims 1 to 3, wherein the peptide is part of a fusion protein, in particular comprising N-terminal amino acids of the HLA-DR antigen-associated invariant chain (Ii). 
Nukleinska kiselina, kodirana za peptid za uporabu s bilo kojim od patentnih zahtjeva od 1 do 4, uz uvjet da peptid nije potpuno humani protein, pri čemu je navedena nukleinska kiselina po mogućnosti DNK, cDNK, PNK, RNK ili kombinacija navedenih, ili ekspresijski vektor koji eksprimira navedenu nukleinsku kiselinu.
The placental stem cells for use according to claim 1, wherein the method is for treatment of mycosis fungoides. 
Matične stanice posteljice za uporabu u skladu s patentnim zahtjevom 8, naznačenu time što navedeno protuupalno antitijelo jest Infliksimab.
The compound of any of claims 9 or 10, wherein Ra is H or C1-C10 alkyl. 
Spoj of any of patentni zahtjevi 9 ili 10, naznačen time što Ra je H ili C1-C10 alkil.
The building block according to claim 1, wherein the diamine and/or polyamine B2) is selected from the group consisting of isophoronediamine and/or a combination of isophoronediamine and a mixture of the isomers of 2,2,4-trimethylhexamethylenediamine and 2,4,4-trimethylhexamethylenediamine. 
Armirani građevni blok prema najmanje jednom od prethodnih patentnih zahtjeva, naznačen time što su prisutni amini B2) odabrani iz skupa koji sadrži izoforondiamin i/ili kombinaciju izoforondiamina i smjese izomera 2,2,4-trimetilheksametilendiamina i 2,4,4-trimetilheksametilendiamina.
The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound is a compound of Formula (Id): 
Tvar iz patentnog zahtjeva 1 ili njena farmaceutski prihvatljiva sol, pri čemu je tvar tvar formule:
to 20 wt.-% of a gel former which is a combination of a (meth)acrylate homopolymer or copolymer and a cellulose derivative, 
od 2 do 20 % tvari za formiranje gela koja predstavlja kombinaciju (met)akrilatnog homopolimera ili kopolimera i derivata celuloze,
An injection assembly according to claim 4, wherein a spring end stands on the movable base (544). 
Injekcijski sklop u skladu s patentnim zahtjevom 4, naznačen time što kraj opruge stoji na pokretnom podnožju
Preparation process according to Claim 15, in which the said residue X is chosen from the group comprising chloride, bromide and iodide. 
18.Proizvodni postupak prema zahtjevu 15, naznačen time, da je navedeni ostatak X odabran iz skupine koju čine klorid, bromid 1 jodid.
mass % A process for the preparation of a treated mineral filler product characterised in that the process comprises the following steps: treating at least one dry mineral filler with at least one Group II or Group III salt of a C8 to C24 aliphatic monocarboxylic acid to produce an intermediate mineral filler product; followed by 
Postupak za pripremu obrađenog mineralno punila naznačen time da postupak sadrži slijedeće korake: a) = obradu najmanje jednog suhog mineralnog punila sa barem jednom soli iz Skupine II ili Skupine III C8 do C24 alifatske monokarboksilne kiseline da se dobije međuprodukt mineralnog punila; te zatim b) obradu međuprodukta mineralnog punila iz koraka (a) sa barem jednom C8 do C24 alifatskom monokarboksilnom kiselinom da se dobije obrađeno mineralno punilo.
Preferably, the antibody selected in step (b) inhibits the binding of an HLA-c allele molecule having a Lys residue at position 80 to a human KIR2DL1 receptor, and the binding of an HLA-C allele molecule having an Asn residue at position 80 to human KIR2DL2/3 receptors. 
Lys ostatak na položaju 80, za humani KIR2DLI receptor, i vezanje HLA-C alel molekule, koja ima Asn ostatak na položaju 80, za humane KIR2DL2/3 receptore.
A salt according to claim 8, wherein the amine is selected from the group consisting of deanol, diethanolamine, diethylethanolamine, ethanolamine, meglumine, 2-morpholine ethanol, 1-(2-hydroxyethyl)-pyrrolidine, triethanolamine and tromethamine. A salt according to claim 9, wherein the amine is selected from the group consisting of meglumine and tromethamine. 
Sol prema zahtjevu 6, naznačena time, što je amin odabran iz grupe koju čine deanol, dietanolamin, dietiletanolamin, etanolamin, meglumin, 2-morfolin etanol, 1-(2-hidroksietil)-pirolidin, trietanolamin i trometamin; poželjno,amin odabran iz grupe koju čine dietanolamin, meglumin, trietanolamin i trometamin; najpoželjnije, amin odabran iz grupe koju čine meglumin i trometamin.
asthma or chronic obstructive pulmonary disease (COPD); 
I) astma ili kronična opstruktivna bolest pluća (COPD);
A solid oral extended release pharmaceutical dosage form comprising an extended release matrix formulation which is cured at a temperature of at least about 60 °C for a time period of at least about 1 minute, the extended release matrix formulation comprising a composition comprising at least: 
barem jedan aktivni agens, i pri čemu je formulacija matrica s produljenim otpuštanjem stvrdnuta pri temperaturi od barem oko 60 °C u vremenskom periodu od oko 1 minute i ima snagu pucanja od barem oko 110 N kada je podvrgnut indentacijskom testu.
to react in the presence of a compound of formula R1SR2 and a chlorine-containing reagent under conditions sufficient to make a mixture comprising a compound of formula (II): and 
(D da reagira u prisutnosti smjese spoja formule R,SR> i trikloroizocijanurne kiseline, pod uvjetima koji su dovoljni da se pripravi spoj formule (II):
a heavy chain variable region CDR3 amino acid sequences are selected from the group consisting of SEQ ID NOs: 16-21; and 
(c) varijabilno područje jakog lanca CDR3 aminokiselinske sekvence odabrane iz skupine koju čine od SEQ ID NO: 16 do SEQ ID NO:21; 1
The process of paragraph 58, wherein the step of converting Compound 10 to Compound 6 comprises reacting Compound 10 with malonic acid. 
Postupak u skladu s patentnim zahtjevom 48, naznačen time što korak prevođenja Spoja 10 u Spoj 6 se sastoji u reakciji Spoja 10 s malonskom kiselinom.
The compound defined by the formula 1 wherein 
Spoj definiran formulom 1 of E
The lighting unit according to claim 1 characterized in that the side of said housing is provided with a mechanical connecting element for connecting a number of lighting units to each other so that their polarizing front units are in the same plane. 
Lampa prema bilo kojem od prethodnih zahtjeva naznačena time što jedna strana kućišta (8) ima mehanički spojni element (10) za spajanje više lampi (22) jednu za drugu tako da njihovi polarizirajući prednji dijelovi (4) budu u istoj ravnini.
to 5% by weight of dyeing agent. 
do 5 težinskih % sredstva za bojenje.
Process according to claim 12, characterised in that said resin is a latex and/or acrylate-based binder, said acrylate-based binder preferably being in the form of an aqueous emulsion. 
Postupak u skladu s patentnim zahtjevom 10 ili 11, karakteriziran na način da je navedena smola lateks i/ili vezivo na bazi akrilata, navedeno vezivo na bazi akrilata je poželjno u obliku vodene emulzije.
represents a 2, 3 or 4-pyridine ring or a 2, 4 or 5-pyrimidine ring, the ring being optionally substituted by a C1-4 alkyl group, a C1-4 alkoxy group, or a halogen atom; represents a benzene ring or a naphthalene ring; the rings being optionally substituted by 1 to 4 substituents selected from a C1-6 alkyl group, a methylendioxy group, a halogen atom, a C1-2 perhalogenated alkyl group, a C1-3 halogenated alkyl group, a hydroxyl group, a C1-4 alkoxy group, a nitro, a cyano, an amino, a C1-5 monoalkylamino group or a C2-10 dialkylamino group; 
R1 znači 2-, 3- ili 4-piridinski prsten ili 2-, 4- ili 5-pirimidinski prsten, prsten izborno supstituiran s Cy4 alkilnom skupinom, Cia alkoksi skupinom ili atomom halogena; R2 predstavlja benzenski prsten ili naftalenski prsten; prstene izborno supstituiran s 1 do 4 supstituenta, koje se bira između C;.« alkilne skupine, metilendioksi skupine, atoma halogena, perhalogenirane Ci. alkilne skupine, halogenirane C,., alkilne skupine, hidroksilne skupine, Cia alkoksi skupine, nitro, cijano, amino, C;.s monoalkilamino skupine ili C2_.;9 dialkilamino skupine;
represents hydrogen, hydroxy, Ar3-oxy, Ar4-C1-4alkyloxy-, C1-4alkyloxy-, C2-4alkenyloxy- optionally substituted with Het12 or R4 represents C1-4alkyloxy substituted with one or where possible two or more substituents selected from C1-4alkyloxy-, hydroxy, halo, Het2-, -NR7R8, -carbonyl- NR9R10 or Het3-carbonyl-; and R6 are each independently selected from hydrogen or C1-4alkyl; 
predstavlja vodik, hidroksi, Ar3-oksi, Ar4-C1-4alkiloksi-, C1-4alkiloksi-, C2-4alkeniloksi- proizvoljno supstituiran sa Het12 ili R4 predstavlja C1-4alkiloksi supstituiran sa jednim ili gdje je moguće sa dva ili više supstituenata koji su odabrani iz skupine koja sadrži C1-4alkiloksi-, hidroksi, halo, Het2-, -NR7R8, -karbonil- NR9R10 ili Het3-karbonil-; i R6 su svaki neovisno odabrani od vodika ili C1-4alkil;
A continuous process for the preparation of (S)-2-acetyloxypropionic acid comprising the following steps: a') distillation of water from an aqueous solution of lactic acid at a concentration comprised from 25 to 60% and replacement with acetic acid by an acetic acid stream, either in liquid or in vapour phase, 
Kontinuirani postupak za pripravu (S)-2-acetiloksipropionske kiseline naznačen time što obuhvaća sljedeće korake: a) destilaciju vode 1z vodene otopine mliječne kiseline pri koncentraciji koja iznosi od 25 do 60% i zamjenu s octenom kiselinom pomoću struje octene kiseline, bilo u tekućoj ili u parnoj fazi, a) o acetilaciju mliječne kiseline u octenoj kiselini s octenim anhidridom, u prisutnosti heterogenog kiselog katalizatora, b) - oporavak (S)-2-acetiloksipropionske kiseline destilacijom octene kiseline.
A pharmaceutical composition, comprising the monoclonal antibody or the antigen-binding portion according to any one of items 1 to 9 and a pharmaceutically acceptable carrier. 
Farmaceutski sastav, naznačen time, da obuhvaća monoklonalno protutijelo ili njegov dio koji se veže na antigen prema bilo kojem od zahtjeva 1 do 6 1 farmaceutski prihvatljiv nosač.
In one embodiment, the invention relates to an antibody, particularly a monoclonal antibody including any functionally equivalent antibody or functional parts thereof according to the present invention and as described herein, wherein said antibody comprises a light chain and a heavy chain variable domain exhibiting an amino acid sequence that is 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the sequences given in SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 18 and SEQ ID NO: 20, or a functional part thereof comprising part or all the heavy and the light chain CDRs. 
HR P20140175 T1 PATENTNI ZAHTJEVI Farmaceutski pripravak namijenjen upotrebi u liječenju glaukoma, optičkog neuritisa ili retikularne distrofije, naznačen time što sadrži terapijski djelotvornu količinu monoklonskog protutijela, ili njegovog funkcionalnog dijela, koje prepoznaje i veže se na B-amiloidni protein, te sadrži CDR1 lakog lanca s aminokiselinskim slijedom SEQ ID NO: 9; CDR2 lakog lanca s aminokiselinskim slijedom SEQ ID NO: 10; CDR3 lakog lanca s aminokiselinskim slijedom SEQ ID NO: 11; CDRI teškog lanca s aminokiselinskim slijedom SEQ ID NO: 12;